In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Feeding the Machine: Exelixis Buys X-Ceptor

Executive Summary

Exelixis' needs to address its increasing burn rate--expected to hit 90 million this year. With a stock mired around $8, any significant equity financing would be dilutive. Partnering was the obvious answer--except that Exelixis didn't have much to partner. By acquiring X-Ceptor Therapeutics it gets a set of much-needed near-term partnering opportunities, and it did so without significantly increasing its projected burn.
Advertisement

Related Content

No Dilution Necessary: The Promise of Project Financing
No Dilution Necessary: The Promise of Project Financing
Exelixis/GSK: Using Project Financing to Accelerate R&D
Cytokinetics Stays the Course
Cytokinetics Stays the Course
Exelixis/GSK: Using Project Financing to Accelerate R&D
Orphan Receptor Drug Discovery
X-Ceptor Therapeutics Inc.
GSK/Exelixis and In-Licensing: Earlier, Richer, Rarer
GSK/Exelixis and In-Licensing: Earlier, Richer, Rarer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel